Arceli Lifescience Private Limited - Due diligence report

A 360° intelligence report on Arceli Lifescience: trust score, financial health, credit view, compliance, directors, growth and distress sig…

2019-04-19 Mumbai, Maharashtra Active Unlisted
Connect MCP
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Arceli Lifescience — 360° Intelligence Report

Generated from MCA filings & public records
69/100
Trust Score
Moderate

Arceli Lifescience is assessed as Moderate with a Trust Score of 69/100. Arceli Lifescience is an active private limited indian non-government company incorporated in 2019, operating in the Chemicals and Materials sector. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 29 Oct 2026 from the latest processed filings. Arceli Lifescience Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
69/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
40/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • Moderate gearing (D/E 38%).
  • Working-capital cover adequate.

Charges position: 1 open (3.36 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
State Bank Of India1 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2025).
  • 2 active GST registration(s).
05

Director Intelligence

Stability score: 40/100
NameDIN / PANDesignationAppointedTenureDIN status
VALLARI ELESH SHAH 01234567 Director 01/04/2018 6 yrs Approved
PALAK PARESH SHAH 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • VALLARI ELESH SHAH has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • 1 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 55 · Distress 65
Growth signals & trust indicators
Asset base grew 1.42 - capacity expansion.
Operating for 7 years.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Outside liabilities up 2.1x in a year.
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence75/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment65/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 3.36 cr already registered.
  • Compliance record supports lending.
Investor view60/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 11 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
15 Mar 2025
Director appointed
VALLARI ELESH SHAH (Additional Director)
Director ceased
ADITYA SURESH SHAH
16 Sep 2022
Charge created
State Bank Of India - 3.36 cr
07 Feb 2022
Securities allotted
3409 Equity Shares - 47.08 Lakh raised
27 Apr 2021
Director ceased
VALLARI ELESH SHAH
12 Mar 2020
Securities allotted
200000 Equity Shares - 20.00 Lakh raised
26 May 2019
Director ceased
MINALI ELESH SHAH
19 Apr 2019
Incorporated
Registered with Roc Mumbai
Director appointed
PALAK PARESH SHAH (Director)
10

Key Observations

Auto-generated from the data above
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); review board churn before relying on management continuity.
2 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Crimson Laboratories Pvt Ltd U24232MP1990PTC005795 .Gwalior, Madhya Pradesh, India
Adam Laboratories Private Limited U24232UP1992PTC014167 Uttar Pradesh, Uttar Pradesh, India
Nymisha Life Sciences Private Limited U24290AP2020PTC115438 Anakapalle, Andhra Pradesh, India
Globespeciality Chemicals Private Limited U24299PN2019PTC182493 Pune, Maharashtra, India
All In One Pharma Private Limited U24290MH2020PTC341989 Panvel, Maharashtra, India
Westerlin Drugs Private Limited U00304BR1990PTC004286 Patna, Bihar, India
Daxon Healthcare Private Limited U24290KL2021PTC072493 Palakkad, Kerala, India
Perduro (Opc) Private Limited U33100CH2016OPC035887 Chandigarh, Chandigarh, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Arceli Lifescience before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Arceli Lifescience: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 55/100, margin trends, ownership structure and peer set for Arceli Lifescience - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 69/100, distress signals and MSME payment-delay disclosures - know whether Arceli Lifescience pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Arceli Lifescience - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Arceli Lifescience an active company?

Arceli Lifescience has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Arceli Lifescience financially healthy?

Arceli Lifescience has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.

Should I do business with Arceli Lifescience?

Its overall Trust Score is 69/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Arceli Lifescience?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Arceli Lifescience have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Arceli Lifescience up to date with its ROC filings?

Balance sheet slightly behind (Mar 2025). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Arceli Lifescience?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.